Searchable abstracts of presentations at key conferences in endocrinology

ea0037ep1219 | Clinical Cases–Pituitary/Adrenal | ECE2015

Autoimmune hypophysitis: from pituitary expansion to empty sella: description of four cases

Marconcini Giulia , Lupi Isabella , Manetti Luca , Cosottini Mirco , Urbani Claudio , Martino Enio , Marcocci Claudio , Bogazzi Fausto

Four patients with autoimmune hypophysitis were followed since the diagnosis of the disease. All presented with severe headache, decreased libido, astenia. Case 1 and 3 presented polyuria and polydipsia. At MRI pituitary was enlarged, with high gadolinum uptake and stalk enlargement.Case 1, male 41 years. MRI volume: AP 13 mm, CC 7 mm. Hormonal assessment: central hypothyroidism, hypoadrenalism, hypogonadism, normal GH and IGF1, hyperprolactinemia, centr...

ea0022p5 | Adrenal | ECE2010

Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome: a longitudinal study

Raffaelli Valentina , Manetti Luca , Ruocco Lucia , Giovannetti Clara , Genovesi Maura , Pellegrini Giovanni , Bogazzi Fausto , Martino Enio

Patients with active Cushing’s syndrome (CS) have an increased coagulability and thrombotic tendency. High glucocorticoids concentrations increase plasma clotting factors, especially von Willebrand factor (vWf) and reduced fibrinolytic capacity. Thromboemobolic complications, mainly in the postsurgical phase, have been reported.Aim of this longitudinal study was to evaluate haemostatic and fibrinolytic markers in patients with active Cushing’s ...

ea0022p564 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Use of cabergolin in Nelson's syndrome: preliminary results in four patients

Giovannetti Clara , Manetti Luca , Raffaelli Valentina , Cosottini Mirco , Genovesi Maura , Martino Enio

The Nelson’s syndrome (NS) is characterized by hyperpigmentation, sellar growing mass, and increased plasma ACTH concentrations The management of NS remains difficult: neurosurgery represent the first choice therapy. Many drugs have been used with variable results: cyproeptadine, GABA-agonists, somatostatin analogues, chemiotherapy, PPAR-γ-agonists, and dopamin-agonists.Aim of this study was to evaluate the efficacy of cabergoline administratio...

ea0022p606 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Impact of rosiglitazone on serum IGF1 concentrations in uncontrolled acromegalic patients under conventional medical therapy: results from a pilot phase 2 study

Lombardi Martina , Rossi Giuseppe , Raggi Francesco , Urbani Claudio , Sardella Chiara , Cosci Chiara , Martino Enio , Bogazzi Fausto

Current therapies for acromegaly are unsatisfactory for some patients. High dose thiazoledinedines have been reported to shrink tumor size and reduce serum GH levels in animal models of acromegaly. To study the effects of increasing doses of rosiglitazone on serum GH and IGF1 concentrations in acromegalic patients, we designed a phase two clinical trial. We enrolled five consecutive patients with active acromegaly uncontrolled under conventional therapies. They received increa...

ea0022p613 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma

Lupi Isabella , Manetti Luca , Caturegli Patrizio , Menicagli Michele , Bevilacqua Genersoso , Bogazzi Fausto , Martino Enio

Serum pituitary antibodies (Pit Abs) and tumor infiltrating lymphocytes (TILs) have been described in a small percentage of pituitary adenomas but their clinical significance remains unknown.Aim of the study was to assess Pit Abs and TILs prevalence in patients with pituitary adenomas and to determine their influence on the clinical outcome. In this prevalence case–control study were enrolled 291 pituitary adenoma cases, (110 non-secreting, 30 ACTH-...

ea0022p765 | Thyroid | ECE2010

Amiodarone-induced thyrotoxicosis in patients with multinodular goiter: type 1 or type 2 AIT?

Tomisti Luca , Dell'Unto Enrica , Brogioni Sandra , Cosci Chiara , Martino Enio , Bogazzi Fausto

Introduction: Type 2 amiodarone-induced thyrotoxicosis (AIT) is a form of destructive thyroiditis, commonly responsive to glucocorticoids. On the contrary, type 1 AIT is an iodine-induced hyperthyroidism, occurring in patients with underlying thyroid disease often responding to thionamides.Aim of the study: To compare the effectiveness of methimazole (MMI) or prednisone (GLU) in the treatment of AIT patients with multinodular goiter with biochemical feat...

ea0014p317 | (1) | ECE2007

Different prevalence of type 1 and type 2 amiodarone-induced thyrotoxicosis over a 30-year period

Tomisti Luca , Dell’Unto Enrica , Cosci Chiara , Sardella Chiara , Bartalena Luigi , Bogazzi Fausto , Martino Enio

Amiodarone induced thyrotoxicosis (AIT) may develop in patients with either underlying thyroid disorders (type 1) or normal gland (type 2). The latter is considered a drug-induced destructive thyroditis, usually responding to glucocorticoids. Further treatments after restoring euthyroidism are often not necessary. The former is a true form of iodine-induced hyperthyroidism the management of which includes thionamides, potassium perchlorate and thyrodectomy. The prevalence of t...

ea0014p572 | (1) | ECE2007

Impairment of GH secretion by ghrelin stimulation test in primary hyperparathyroidism (PHP)

Cecconi Elisabetta , Giovannetti Clara , Manetti Luca , Raffaelli Valentina , Procopio Massimo , Ghigo Ezio , Gasperi Maurizio , Martino Enio

Pituitary GH secretion is regulated by the interplay of at least two hypothalamic hormones, GH-releasing hormone (GHRH) and somatostatin, through their interaction with specific cell surface receptors on the anterior pituitary somatotrophs. A third type of receptor, the growth hormone secretagogue receptor, called GHS receptor type 1a (GHSR1a), was identified in the pituitary and the hypothalamus. Ghrelin is an acylated peptide produced predominantly by stomach and a natural l...

ea0014p626 | (1) | ECE2007

Androgenicity, androgen receptor polymorphism and pharmacogenetics

Canale Domenico , Moschini Cecilia , Caglieresi Carolina , Moscatelli Agnese , Gavioli Silvia , Macchia Enrico , Martino Enio

Exon 1 of the androgen receptor (AR) gene contains a variable number of CAG triplets, (CAGr)n which encode a polyglutamine stretch of variable length in the N-terminal domain of the receptor. Experimental evidence has accumulated in demonstrating that the length of this stretch influences the transcriptional activity induced by the AR and therefore modulates target organs responsiveness to androgens.The (CAGr)n is inversely associated with the transcript...

ea0014p571 | (1) | ECE2007

Riluzole treatment does not affect growth hormone (GH) secretion in amyotrophic lateral sclerosis

Morselli Lisa Linda , Bongioanni Paolo , Genovesi Maura , Licitra Rosaria , Rossi Bruno , Murri Luigi , Gasperi Maurizio , Martino Enio

Amyotrophic lateral sclerosis (ALS), the most common motor neurone disorder in human adults, presents is characterized by selective and progressive degeneration of upper and lower motor neurones in central nervous system. GH secretion, evaluated by GHRH+arginine test, has been recently reported to be impaired in about 70% of untreated ALS patients. The currently available drug for ALS treatment is riluzole, a compound acting through inhibition of glutamate relase, post-synapti...